Home/Products/RITEPOD 200 CV TAB
RITEPOD 200 CV TAB
— Product

RITEPOD 200 CV TAB

CEFPODOXIME 200MG + CLAUV ACID 125MG

RITEPOD 200 CV TAB is a tablet combining cefpodoxime 200 mg with clavulanic acid 125 mg. The clavulanate protects the cefpodoxime from bacterial beta-lactamase, extending its cover to resistant organisms in respiratory, urinary, skin and soft-tissue infections.

Enquire about this product → Back to catalog
01

Benefits

  • Clavulanate inhibits beta-lactamase, restoring cefpodoxime's activity against organisms that would otherwise inactivate it.
  • Retains cefpodoxime's broad Gram-positive and Gram-negative spectrum.
  • A useful escalation where a plain cephalosporin course has failed or resistant organisms are likely.
  • Twice-daily oral dosing keeps the regimen practical.
  • Provides an oral option in infections that might otherwise need injectable therapy.
02

Side effects

Not everyone gets these. Most are mild and settle as the course finishes.

Common
  • Diarrhoea, which is more frequent than with cefpodoxime alone
  • Nausea or vomiting
  • Abdominal discomfort
  • Skin rash
Less common
  • Oral or vaginal thrush after the course
  • Raised liver enzymes on testing
  • Headache or dizziness
  • Indigestion
Stop and get medical help if any of these occur
  • Swelling of the face, lips or tongue, difficulty breathing, or collapse
  • Yellowing of the skin or eyes, dark urine, or pale stools
  • Severe, watery or bloody diarrhoea during or in the weeks after the course
  • Widespread rash with blistering or peeling skin
  • Reduced urine output
03

Precautions

  • Contraindicated in known cephalosporin allergy; use with caution in penicillin allergy and avoid after penicillin anaphylaxis.
  • Clavulanate carries a risk of cholestatic jaundice, more so in the elderly and with prolonged courses. Keep courses short.
  • Take with food, which improves cefpodoxime absorption and reduces diarrhoea.
  • Avoid antacids and proton pump inhibitors around the dose, as cefpodoxime absorption requires gastric acid.
  • Dose reduction is required in significant renal impairment.
  • Reserve for cases where a beta-lactamase inhibitor is genuinely needed rather than using it first-line.
  • Complete the full prescribed course.